BRAF and neoplasm: Sorafenib is an oral multikinase inhibitor that mainly targets kinases involved in tumor cell growth and angiogenesis such as Raf kinases (CRAF, BRAF, V600E BRAF) and tyrosine kinases (FLT3, Kit, VEGFR2/3 and PDGFRB) [5].